IMVT
Immunovant, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.44
+1.36%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$29.82
From 52W high−34.53%
Volume253480.00
Market cap$6.08B
P/E (TTM)—
P/S (TTM)857.0x
Div yield—
Key dataNov 4, 2026
Open
$29.82
From 52W high
−34.53%
Volume
253480.00
Market cap
$6.08B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.8x
P/E (TTM)
—
RSI (14)
41.6
MomentumView details →
1D Return
+1.36%
YTD Return
+14.67%
SummaryUpdated Jun 1, 2026
Immunovant, Inc. (NASDAQ:IMVT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in New York, New York. The company went public in June 2019 and operates as a subsidiary of Roivant Sciences Ltd. Immunovant focuses on developing innovative monoclonal antibody treatments for autoimmune diseases, with its lead drug candidate batoclimab currently advancing through multiple Phase II clinical trials for various autoimmune conditions.
Similar companies
Latest newsMore news →
Immunovant announced that it will report financial results for the fiscal second quarter ended September 30, 2026, on November 9, 2026, before the market opens.14d agoKuehn Law, PLLC said it is investigating whether Immunovant officers and directors breached fiduciary duties to shareholders through potential self-dealing.23d ago